Rheumatic Disorders Treatment Market: By Disease (Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Gout, and Others), By Treatment (Narcotic Analgesics, NSAIDS, Corticosteroids, Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Response Modifiers (Monoclonal Antibodies (mAb), TNF Inhibitors, Interleukin (IL) Inhibitors, JAK inhibitors), and Others), and Geography    

Rheumatic Disorders Treatment Market size was valued at USD 64.02 billion in 2022, growing at a CAGR of 5.2% from 2023 to 2029. The global market provides a detailed overview and that can be segmented by disease and by treatment. By disease, the global rheumatic disorders treatment market has been segmented into Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Gout, and Others. The Rheumatoid Arthritis segment is likely to be the largest and fastest-growing segment in terms of type in 2021 and is expected to maintain the trend in the forecasted years. This is due to the increasing prevalence of rheumatoid arthritis. Based on treatment, the global rheumatic disorders treatment market is segmented into Narcotic Analgesics, NSAIDS, Corticosteroids, and Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Among these, the Disease-Modifying Anti-Rheumatic Drugs (DMARDs) segment is expected to have the fastest-growing market during the forecast period 2022-2028 according to Precision Business Insights. The rise in the incidence of a number of indications within the rheumatic disorders and increase in prevalence of geriatric population are the major factors that are driving the growth of the market in 2022 and are expected to maintain a significant CAGR in the upcoming years.

Rheumatic Disorders Treatment Market Key Development:

• In Aug 2022, Lilly completes Phase II rheumatoid arthritis trial successfully.